Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EFZO-CONNECT: Efzofitimod in SSc-ILD
NCT05892614Phase 2Recruiting
- Sponsor
- aTyr Pharma
- Start
- Oct 2023
- Primary completion
- Apr 2026
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of efzofitimod in Systemic sclerosis-related interstitial lung disease (SSc-ILD) (3 arms), sponsored by aTyr Pharma. Primary endpoints: Absolute change from baseline in forced vital capacity at 24 weeks, Annual rate of decline in forced vital capacity (mL) at 24 weeks and 2 more. Started Oct 2023; status: recruiting.
02
Drugs
efzofitimod
03
Conditions
Systemic sclerosis-related interstitial lung disease (SSc-ILD)
Beyond the preview
Go deeper on NCT05892614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05892614.